Jazz Pharmaceuticals (NASDAQ: JAZZ) lost one of its development-stage drugs today when an FDA panel vetoed JZP-6, which was designed to treat Fibromyalgia, a painful nervous disorder. According to Reuters, one of the main reasons for the denial was the presence of hydroxybutyrate (GHB) which is known colloquially as “the date rape drug.”
The panel voted overwhelmingly against the drug (20-2) with panelists explaining their main reasons were concerns for abuse, as well as a lack of proof that the drug will perform any better than current treatments. The panel was not entirely pessimistic, and suggested Jazz go back to the drawing board on the treatment.
-Michael B. sauter